SYK (Spleen tyrosine kinase)

News alerts, weekly reports and conference planners

Entrez ID:

SYK mutation	Non Small Cell Lung Cancer	SYK mutation	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
SYK mutation	Melanoma	SYK mutation	Melanoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
EGFR mutation + SYK overexpression	Non Small Cell Lung Cancer	EGFR mutation + SYK overexpression	Non Small Cell Lung Cancer	EGFR inhibitor Sensitive: C3 – Early Trials EGFR inhibitor Sensitive : C3	EGFR inhibitor Sensitive: C3 – Early Trials EGFR inhibitor Sensitive : C3
MET overexpression + SYK overexpression	Non Small Cell Lung Cancer	MET overexpression + SYK overexpression	Non Small Cell Lung Cancer	gumarontinib Sensitive: D – Preclinical gumarontinib Sensitive : D	gumarontinib Sensitive: D – Preclinical gumarontinib Sensitive : D
MET overexpression + SYK overexpression	Non Small Cell Lung Cancer	MET overexpression + SYK overexpression	Non Small Cell Lung Cancer	capmatinib Sensitive: D – Preclinical capmatinib Sensitive : D	capmatinib Sensitive: D – Preclinical capmatinib Sensitive : D

Associations(5)